Erectile Dysfunction Drugs Market is Expected to Reach an Estimated value of US$3.4 billion by 2019, Down From a Value of US$4.3 Billion in 2012: Transparency Market Research

News provided by

Sep 09, 2015, 08:30 ET

ALBANY, New York, September 9, 2015 /PRNewswire/ --

Erectile dysfunction drugs are one of the most popular methods of treating erectile problems caused due to anxiety, stress, or relationship problems. Transparency Market Research's new market report, titled 'Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019', states that the global erectile dysfunction drugs market is expected to decline in the coming years.By 2019, the market is expected to reach an estimated value of US$3.4 billion, down from a value of US$4.3 billion in 2012. According to the data presented in this report, the global erectile dysfunction drugs market is anticipated to decline at a CAGR of -4.5% during the forecast period from 2013 to 2019. According to analysts at TMR, the global erectile dysfunction drugs market is primarily driven by the rising geriatric population in major regions of the world. The demand for erectile dysfunction drugs is also growing due to the rise in the incidence of various diseases, shifting consumer preference towards a sedentary lifestyle, and increasing focus on awareness and physical education regarding the drugs used for erectile dysfunction.

Browse Market Research Report with ToC & Free Analysis: http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html

The growing impact of clinical trials and tests for erectile dysfunction drugs also contribute to the growth in this market. Some of the current trends in the market are innovative drug delivery, new test techniques, blockbuster patent expirations, and molecule combinations - all offering plenty of growth opportunities in the global erectile dysfunction drugs market. Although various merits are propelling the erectile dysfunction drugs market, some factors also impede the acceptance of these drugs all around the world. The growing threat from counterfeit drugs in the market, prevalence of sexually transmitted diseases with ED drug users, and narrowing of insurance coverage for erectile dysfunction treatment are some of the major market restraints.In the recent past, the market witnessed an end of patent exclusivities, which has further cut down the revenue of the global erectile dysfunction drugs market. The market will also experience a low growth rate due to the weak pipeline development in terms of new drug formulations. Overall, the market is on the verge of suffering a big setback before the end of the forecast period.

Get Sample Report Copy: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1550

Based on brand, this study report divides the market into Stendra/Spedra, Viagra, Cialis, MUSE, Mvix, Levitra/Staxyn, Zydena, and Helleva. Viagra accounted for the largest share in the overall market. By revenue, Viagra held a 45% share of the total erectile dysfunction drugs market. However, due to expiration of patents of the Viagra drug, especially outside the U.S. in 2013, the availability of Viagra has declined.

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/erectile-dysfunction-drugs.htm

However, according to analysts at TMR, Viagra will continue to maintain a major revenue share in the U.S. erectile dysfunction drugs market due to extended patent exclusivity till 2020. The market for Cialis (tadalafil) is also estimated to witness a decline in terms of market revenue. In 2012, Cialis stood at US$1,926.8 million, accounting for the second largest share in the overall market. However, it is expected to decline at a CAGR of -12.6% in the forecast period 2013-2019.

Browse Article: http://www.transparencymarketresearch.com/article/erectile-dysfunction-drugs.htm

Major geographies analyzed under this research report are:

Europe
North America
Asia-Pacific
Rest of the World

This report gives you access to decisive data such as:

Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for the coming years

Browse Other Reports of Transparency Market Research:

Dyslipidemia Drugs Market: http://www.transparencymarketresearch.com/dyslipidemia-market.html

Healthcare Business Intelligence Market: http://www.transparencymarketresearch.com/healthcare-business-intelligence.html

Noscapine Base Market: http://www.transparencymarketresearch.com/noscapine-base-market.html

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact
Transparency Market Research
Mr. Nachiket Ghumare
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]